

BP medicine by Glenmark gets USFDA nod

26 May 2017 | News

Glenmark's Olmesartan Medoxomil tablets will be manufactured by the company's manufacturing facility located in Goa, India.



Glenmark Pharmaceuticals received final approval from the US health regulator for its generic version Olmesartan Medoxomil Tablets, used in treatment of high blood pressure.

The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg.

These are the generic equivalent of Benicar Tablets of Daiichi Sankyo, Inc.

Glenmark's Olmesartan Medoxomil tablets will be manufactured by the company's manufacturing facility located in Goa, India.

Citing IMS Health sales data for the 12-month period ended March 2017, Benicar achieved annual sales of about \$950 million.

Glenmark's current portfolio consists of 115 products authorised for distribution in the US market and approximately 69 ANDA's (Abbreviated New Drug Application) pending approval with the USFDA.